Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Francine Fein"'
Autor:
Emeline Orillard, Julie Henriques, Dewi Vernerey, Hamadi Almotlak, Fabien Calcagno, Francine Fein, Serge Fratté, Marine Jary, Elodie Klajer, Angelique Vienot, Christophe Borg, Stefano Kim
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundStudies have reported a beneficial role of the addition of trastuzumab to platin-5-FU based chemotherapy in first-line advanced HER2 positive gastroesophageal adenocarcinoma (GEA). However, the effect of taxanes combined with platin-5FU + t
Externí odkaz:
https://doaj.org/article/57e113288c4c4987b99eabfc7487b9b2
Autor:
Cindy Serdjebi, Johan Gagnière, Jérôme Desramé, Francine Fein, Rosine Guimbaud, Eric François, Thierry André, Jean-François Seitz, Carole Montérymard, Dominique Arsene, Julien Volet, Abakar Abakar-Mahamat, Thierry Lecomte, Véronique Guerin-Meyer, Jean-Louis Legoux, Gaël Deplanque, Pierre Guillet, Joseph Ciccolini, Côme Lepage, Laetitia Dahan
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135907 (2015)
Because cytidine deaminase (CDA) is the key enzyme in gemcitabine metabolism, numerous studies have attempted to investigate impact of CDA status (i.e. genotype or phenotype) on clinical outcome. To date, data are still controversial because none of
Externí odkaz:
https://doaj.org/article/55333137924b4b87813ce2431fa811d4
Autor:
Amélie Anota, Guillaume Mouillet, Isabelle Trouilloud, Anne-Claire Dupont-Gossart, Pascal Artru, Thierry Lecomte, Aziz Zaanan, Mélanie Gauthier, Francine Fein, Olivier Dubreuil, Sophie Paget-Bailly, Julien Taieb, Franck Bonnetain
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0125350 (2015)
A randomized multicenter phase II trial was conducted to assess the sequential treatment strategy using FOLFIRI.3 and gemcitabine alternately (Arm 2) compared to gemcitabine alone (Arm 1) in patients with metastatic non pre-treated pancreatic adenoca
Externí odkaz:
https://doaj.org/article/501a408888f74184b7b154c131947648
Autor:
Elodie Klajer, Marine Jary, Angélique Vienot, Aurélia Meurisse, Francine Fein, Clément Bolognini, Syrine Abdeljaoued, Hortense Chevalier, Dewi Vernerey, Meher Nasri, Anthony Turpin, Stefano Kim, Hamadi Almotlak, Thierry Nguyen, Christophe Borg, Elisabeta Gherga, Fabien Calcagno, Christelle d’Engremont
Publikováno v:
World Journal of Gastrointestinal Oncology. 12:332-346
FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study
Autor:
Aurélia Meurisse, S.-B. Kim, L. Chanut, M. Nasri, Elodie Klajer, M. Rebucci-Peixoto, Marine Jary, J. Babre, T. Nguyen, S. Fratte, Julie Henriques, Francine Fein, Dewi Vernerey, Angélique Vienot, Hamadi Almotlak, Christophe Borg, Laurie Spehner, Fabien Calcagno
Publikováno v:
Annals of Oncology. 32:S581
Autor:
Cindy Serdjebi, Eric Francois, Bruno Lacarelle, Gael Deplanque, Joseph Ciccolini, Jean-François Seitz, Madani Rachid, Laetitia Dahan, Abakar Abakar-Mahamat, Florence Gattacceca, Johan Gagnière, Francine Fein
Publikováno v:
Therapeutic Drug Monitoring. 39:290-296
Gemcitabine remains a pillar in pancreatic cancer treatment. However, toxicities are frequently observed. Dose adjustment based on therapeutic drug monitoring might help decrease the occurrence of toxicities. In this context, this work aims at descri
Autor:
Franck Bonnetain, Frédéric Fiteni, Sophie Paget-Bailly, Marine Jary, Mathieu Messager, Christophe Mariette, Denis Cléau, Zaher Lakkis, Stefano Kim, Pierre Mathieu, Najib Lamfichekh, N. Sakek, T. Nguyen, Francine Fein, A. Foubert, S. Fratte, Christophe Borg, Marion Jacquin
Publikováno v:
European Journal of Surgical Oncology (EJSO). 43:218-225
Background Even though the perioperative chemotherapy improves the overall survival (OS) compared to surgery alone in patients with a resectable gastroesophageal adenocarcinoma (GEA), prognosis of these patients remains poor. Docetaxel (D), cisplatin
Autor:
Thierry Nguyen, Zaher Lakkis, Stefano Kim, Marine Jary, Francine Fein, Christophe Borg, Francine Arbez-Gindre, Marion Jacquin, Anne Cayre
Publikováno v:
Clinical Colorectal Cancer. 15:e229-e234
Autor:
Angélique, Vienot, Hortense, Chevalier, Clément, Bolognini, Elisabeta, Gherga, Elodie, Klajer, Aurélia, Meurisse, Marine, Jary, Stefano, Kim, Christelle, d'Engremont, Thierry, Nguyen, Fabien, Calcagno, Hamadi, Almotlak, Francine, Fein, Meher, Nasri, Syrine, Abdeljaoued, Anthony, Turpin, Christophe, Borg, Dewi, Vernerey
Publikováno v:
World Journal of Gastrointestinal Oncology
BACKGROUND FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal adenocarcinoma (aPDAC). FOLFOXIRI, a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil, has demonstrated efficacy and feasibi
Autor:
C Emont, D. Cazaux, P Sage, Francine Fein, I. Tchoumak, A Chupin, G Claudé, Julienne Grillot, Claire Vanlemmens, Stéphane Koch, Thierry Thevenot, C Briot, C. Prothe, G Boivineau, C Biron, O Comiti, M. Stouvenot, J.-P. Cervoni, V. Di Martino, Lucine Vuitton, C D'engremont, T Deregnaucourt
Publikováno v:
Journées Francophones d'Hépato-Gastroentérologie et d'Oncologie Digestive (JFHOD).